The members of the advisory board agreed that clinical chemistry and laboratory tests can certainly, in the early stages of the diagnostic process, lead towards the exclusion of FGF23-independent forms of hypophosphatemia. The gene discussed is FGF23; the disease is hypophosphatemia.